🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Advanced #ProstateCancer: Understanding out-of-pocket medication costs. Daniel Joyce, MD, MS joins Ruchika Talwar Vanderbilt Urology in this important discussion on the financial impact of advanced #PCa treatments on patients. #WatchNow on UroToday > bit.ly/3ADoASf

📢 Attention Society of Urologic Oncology applicants! The Mayo Clinic Urology Urologic Oncology Fellowship in Rochester, MN is now open for applications for the 2026 match. 🗓️Application Deadline: February 1, 2025 Apply here: bit.ly/415tB1n YUO

Great people, great place. Formative experience in my training. Best SUO clinical training there is!

📣 Attention Society of Urologic Oncology applicants! Apply now for the Mayo Clinic Urology Urologic Oncology Fellowship in Rochester, MN for the 2026 match! 🗓️ Application deadline February 1, 2025 Apply here: bit.ly/415tB1n YUO

KIM-1, linked to immune biology, appears the best prognosis biomarker for kidney cancer. A ⬇️ at 3 wks is higher for sunitinib than ipi/nivo but the fall predicts responses to ipi/nivo only. We should start exploring this circulating marker for prognosis and immune therapy #GU25

Save the Date for the #VUS2025 Annual Meeting, September 29-30, 2025 in Nashville, Tennessee! Join urology professionals and students to gain the latest insights from world-class speakers and panels, while connecting and socializing with VUS colleagues and peers. #VUS #urology

National complication and cost burden of TURBT UCLA Urology Mayo Clinic Urology VirginiaMasonUrology Vanderbilt Urology UTMBUrology sciencedirect.com/science/articl…

I can genuinely say that this resource is hands down the best out there for boards studying. It has everything you need. An awesome accomplishment by Ben Dropkin

🔊 Drs. Sam Chang (Sam S. Chang MD, MBA) and Daniel Joyce of Vanderbilt University Medical Center sit down to take a comprehensive look at the latest QUILT-3.032 study: buff.ly/4NLcmoO 📺 The doctors discuss topics including complete responses to N-803 plus #BCG in patients with BCG-unresponsive

📺 Reuben Ben-David ד''ר ראובן בן דוד of Icahn School of Medicine at Mount Sinai, and Daniel Joyce, MD, of Vanderbilt University Medical Center, share the reasoning and findings of an analysis on the pathological and clinical features associated with preoperatively detectable #ctDNA: buff.ly/BZG3im3

healthaffairs.org/doi/full/10.13…

⬆️ Elevated levels of kidney injury molecule-1 (KIM-1) may serve as a prognostic biomarker for patients with metastatic #RCC, according to data presented at ASCO #ASCO25: buff.ly/h4XKFgm 🔎 The analysis demonstrated that elevated levels of KIM-1 at baseline were

Perspective by Thomas J. Hwang, MD (Thomas Hwang, MD), Nancy L. Keating, MD, MPH, and Stacie B. Dusetzina, PhD: Biologic Drugs and Medicare Price Negotiation nej.md/44egmLM #HealthPolicy

Viewpoint: Cabozantinib capsules are more cost-effective than tablets for treating various cancers, and adopting capsule-based dosing strategies could reduce costs while maintaining efficacy. ja.ma/4l4zJ0o

Trimodal therapy was associated with improved quality of life, but was not a cost-effective strategy for management of muscle-invasive bladder cancer relative to radical cystectomy. ja.ma/43XxR42

📢 New publication alert! Stephen B. Williams, MD, MBA, MS, FACHE and the expert team at @UTMBHealth UTMBUrology share critical insights in JAMA Network Open on cost effectiveness for advanced bladder cancer treatments. 🔗 Read the full study: jamanetwork.com/journals/jaman… #UroOnc #BladderCancer #JAMA

Cost-Effectiveness of Therapies for Muscle-Invasive Bladder Cancer jamanetwork.com/journals/jaman…

With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to say ‘pick one and use it well’. #GUARDSymposium2025 Ipi/nivo is less good at getting initial control but has less long term toxicity. Brian Rini, MD OncoAlert